## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%); PEG 3.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($556.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. DGIST Receives Surgical Robot Research Platform Donated from Global Medical Robotics Company Intuitive Surgical**
- Source: Asia Research News | | 20251226T020808 | Bullish | Relevance: 100%
- DGIST has received a donation of a dVRK surgical robot research platform from Intuitive Surgical, making it the sixth institution in Asia to join the global surgical robot research network. This platform will enable Professor Minho Hwang's team to advance research in next-generation surgical technologies, including AI-based automation and precision control. The donation aims to establish DGIST as a hub for intelligent surgery technology and foster collaboration within the international research community.

**2. The Bull Case For Intuitive Surgical (ISRG) Could Change Following Expanded da Vinci SP FDA Clearance**
- Source: Simply Wall Street | 20251225T214529 | Bullish | Relevance: 100%
- Intuitive Surgical recently received expanded FDA clearance for its da Vinci Single Port system to include common general surgery procedures, significantly broadening its applications. This expanded procedural toolkit, coupled with digital and AI enhancements, is expected to deepen the company's role in minimally invasive surgery and influence hospital investment strategies. The new clearance supports higher procedure volumes and system utilization, reinforcing Intuitive Surgical's growth narrative despite ongoing risks like a Class 2 recall and international budget constraints.

**3. Intuitive Surgical (ISRG) News, Analyst Forecasts and 2026 Outlook: FDA Expansion for da Vinci SP, Wall Street Targets, and Whatâ€™s Next (Dec. 25, 2025)**
- Source: ts2.tech | 20251225T213529 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) is closing 2025 with significant developments, including FDA clearance for expanded indications for its da Vinci SP system in high-volume general surgery, and a strategic shift towards digital and AI integration. While the robotic surgery leader shows strong procedure growth and a robust installed base, analysts maintain a "Moderate Buy" rating, focusing on flawless execution to justify its premium valuation. Investors are keenly awaiting the Q4 2025 earnings report and 2026 guidance for insights into growth drivers and margin sustainability.

**4. Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?**
- Source: The Globe and Mail | 20251224T130836 | Somewhat-Bullish | Relevance: 100%
- This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major MedTech companies, evaluating their upside potential based on growth leverage, revenue visibility, and strategic positioning. While Stryker offers diversification and stability, Intuitive Surgical, with its concentrated robotics exposure and higher margins, is suggested to have greater upside potential. However, ISRG carries higher valuation sensitivity and competition risks compared to SYK's steadier, but perhaps less explosive, growth profile.

**5. Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?**
- Source: Finviz | 20251224T093000 | Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) has an average brokerage recommendation (ABR) of 1.73, indicating a strong buy to buy sentiment from analysts. While brokerage recommendations often have a positive bias due to vested interests, the article suggests using this information to validate analysis with reliable tools like the Zacks Rank. The Zacks Rank for ISRG is currently #2 (Buy), driven by a 0.6% increase in the consensus estimate for the current year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $650 | $620 | +5% |
| 2025-12-17 | RBC Capital | $650 | $625 | +4% |
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 5 ($2.98M) |
| Sells | 13 ($5.48M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Insider selling cluster: $5.5M in recent transactions.
2. Valuation stretched: PEG 3.5x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.55 signals overvaluation risk, limited margin of safety. Forward P/E 59.3x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $207.1B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.55 |
| Forward P/E | 59.3 |
| Current P/E | 66.9 |
| YoY Growth | 12.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.5% to 0.6% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.60), confirming momentum. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.64% (CS: 85) | Neutral |
| RSI_14 | 61.0 | Neutral |
| MACD Histogram | 0.60 | Bullish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 1.134x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $577.81
- **Stop Loss:** $556.09 (3.8% risk)
- **Target:** $599.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $34,668.60
- **Portfolio %:** 34.67%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*